

FINE: Imaging fibrosis in lung cancer and relating findings to outcomes of treatment

Submission date 17/11/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 15/02/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 06/12/2023	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Lung cancer is the leading cause of cancer related death worldwide and most patients have progressive disease or relapse despite therapy and new therapies that target the immune system. The tumour microenvironment (TME) is a collection of several different cell types, including a cell called fibroblasts. The fibroblasts within lung cancer express a protein called FAP and this protein can now be imaged using scans called PET scans. Therefore, using imaging (with a specialised PET scan) could allow us to determine which patients have a FAP active tumour, and which do not, which in turn could inform us as to which patients may need additional treatments targeting the TME/fibroblasts to help therapy be more effective. This study looks to lay the foundations for the use of PET imaging of FAP in NSCLC by using small numbers of patients who have been diagnosed with lung cancer and perform a FAP-PET scan at a single time point, following which the patients all receive their usual standard care. We will recruit patients who are planned to have surgical excision of the tumour, as well as patients who are due to have drug based anti-cancer therapy (including immune targeting regimes). This study looks to help us understand if the FAP-PET signal corresponds to i) the amount of FAP active fibroblasts in a tumour and ii) if this can potentially indicate subsequent failure of treatment, prior to subsequent larger trials.

Who can participate?

Participants aged over 50 years old with confirmed lung cancer who are either undergoing planned surgical resection (cohort 1) or planned systemic oncological treatment (cohort 2)

What does the study involve?

The study involves eligible participants undergoing a research PET scan. They may also be asked to provide a small blood sample, up to 20mls. If the participant is on the surgical pathway (cohort 1), we will also obtain a sample of lung tissue following surgery. Participants clinical records will be followed-up for up to 1 year

What are the potential benefits and risks of participating?

The PET scan is an extra scan in addition to routine care, therefore there is small increase in the amount of radiation exposure.

There is a potential risk of an allergic reaction to the radiotracer which is very rare (serious

allergic reactions occur in approximately 1 in 10,000 patients) and we have clear procedures for managing such reactions. There is also a small risk of bleeding, bruising and infection from the cannula insertion but we will follow a sterile procedure.

Where is the study run from?

Royal Infirmary of Edinburgh (UK)

When is the study starting and how long is it expected to run for?

April 2021 to December 2023

Who is funding the study?

Cancer Research UK

Who is the main contact?

Dr Ahsan Akram, ahsan.akram@ed.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Ahsan Akram

ORCID ID

<http://orcid.org/0000-0003-4605-1682>

Contact details

University of Edinburgh
Centre For Inflammation Research
The Queen's Medical Research Institute
47 Little France Crescent
Edinburgh
United Kingdom
EH16 4TJ
+44 (0)131 2429180
ahsan.akram@ed.ac.uk

Type(s)

Public

Contact name

Mrs Katie Hamilton

Contact details

University of Edinburgh
Centre For Inflammation Research
The Queen's Medical Research Institute
47 Little France Crescent
Edinburgh
United Kingdom

EH16 4TJ
+44 (0)131 2429180
k.hamilton@ed.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

299962

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

AC21071, IRAS 299962, CPMS 51140

Study information

Scientific Title

Imaging Fibroblast Activation Protein (FAP) in non-small cell lung cancer using PET scan and correlation with outcomes of usual therapy.

Acronym

FINE

Study objectives

Can fibrosis activity (measured by FAP specific PET-CT) be correlated with the response to therapy in non-small cell lung cancer?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 27/08/2021, West of Scotland REC 5 (West of Scotland Research Ethics Service, Ward 11, Dykebar Hospital, Grahamston Road, PAISLEY, PA2 7DE, UK; +44 (0)141 314 0213; WoSREC5@ggc.scot.nhs.uk), ref: 21/WS/0094

Study design

Single-site observational cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

See study outputs table

Health condition(s) or problem(s) studied

Lung cancer

Interventions

Eligible participants from both cohorts, will undergo a research scan (PET-CT scan using the FAP radiotracer) and it is possible the eligibility assessment/consent occur on the same day as the scan. Blood will be drawn at consent and at the time of the PET-CT scan if on separate days.

Cohort 1 will undergo resection of their tumour and once the specimen has been resected areas of tumour and non-cancerous lung will be dissected by a trained pathologist of ex-vivo assays undertaken in the University of Edinburgh. The surgical resection forms part of the routine care. The additional specimens taken by the research team form part of the study. No further study interventions will be undertaken with cohort 1, though in an observational manner the cohort will have their notes reviewed for up to 1 year for outcome metrics.

Cohort 2 will include patients who are referred to medical oncology for systemic anti-cancer therapy. Following the PET-CT, no further study interventions will be undertaken with cohort 2, though in an observational manner the cohort will have their notes reviewed for up to 1 year for outcome metrics, including routine care CT scans that may be undertaken.

Intervention Type

Other

Primary outcome measure

Cohort 1 (measured at the time of resection):

1. The degree of fibrosis on the 68Ga-FAPI scan measured by SUV (standardised uptake volume) over a ROI (region of interest)
2. Markers of fibroblast activation from the excised tissue (measured by multiparametric flow cytometry analysis), including FAP, CD34, aSMA, podoplanin)

Cohort 2:

1. The degree of fibrosis on the 68Ga-FAPI scan measured by SUV (standardised uptake volume) over a ROI (region of interest) measured at the time of resection
2. Treatment response measured by visual inspection of CT scan using RECIST and iRECIST methods post treatment and on usual scans up to 1 year

Secondary outcome measures

Cohort 1: Laboratory markers including T-cell phenotypes within the tumour measured using biopsy at the time of resection

Cohort 2: Progression free survival and mortality measured using patient records up to 1 year

Overall study start date

16/04/2021

Completion date

31/12/2023

Eligibility

Key inclusion criteria

1. Capacity to provide informed consent
2. Confirmed lung cancer for which surgical resection is being planned (Cohort 1)
3. Confirmed lung cancer (cohort 2) planned for systemic oncological treatment
4. Treatment naïve patients ≥50 years
5. Thoracic CT scan taken within the previous 12 weeks
6. ECOG performance status 0-2

Participant type(s)

Patient

Age group

Adult

Lower age limit

50 Years

Sex

Both

Target number of participants

Cohort 1: 5 patients, cohort 2: 10 patients

Total final enrolment

15

Key exclusion criteria

1. Inability or unwilling to give informed consent.
2. Unable to tolerate the supine position
3. Impaired renal function with eGFR of $<30 \text{ mL/min/1.73m}^2$
4. Severe or significant comorbidity that prevents systemic oncological therapy or performance status 3 or 4
5. Women who are pregnant or breastfeeding

Date of first enrolment

19/11/2021

Date of final enrolment

10/10/2022

Locations

Countries of recruitment

Scotland

United Kingdom

Study participating centre
Royal Infirmary of Edinburgh
51 Little France Crescent
Old Dalkeith Road
Edinburgh
United Kingdom
EH16 4SA

Sponsor information

Organisation
University of Edinburgh

Sponsor details
The Queen's Medical Research Institute
47 Little France Crescent
Edinburgh
Scotland
United Kingdom
EH16 4TJ
+44 (0)1312423326
resgov@accord.scot

Sponsor type
University/education

Website
<https://www.accord.scot>

ROR
<https://ror.org/01nrxf90>

Organisation
NHS Lothian

Sponsor details
University of Edinburgh
Centre For Inflammation Research
The Queen's Medical Research Institute
47 Little France Crescent
Edinburgh
Scotland

United Kingdom
EH16 4TJ
+44 (0)1312423325
accord@nhslothian.scot.nhs.uk

Sponsor type

Hospital/treatment centre

Website

<https://www.accord.scot>

ROR

<https://ror.org/03q82t418>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The results of this study will be published in peer reviewed journals and disseminated to clinical colleagues

Intention to publish date

29/06/2024

Individual participant data (IPD) sharing plan

The datasets generated during and during the current study will be available upon request from the study team following completion of the study. (ahsan.akram@ed.ac.uk)

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version 2	24/08/2021	17/11/2021	No	Yes
HRA research summary			28/06/2023	No	No